India, June 6 -- BioCryst Pharmaceuticals (BCRX) announced that ORLADEYO (berotralstat) has been approved for national reimbursement in the Netherlands for routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 and above.
This milestone means ORLADEYO now has reimbursement coverage in all major European countries, offering the first oral, once-daily preventive treatment for HAE.
Abid Karim, BioCryst's European general manager, stated that this marks a significant achievement in expanding patient access across Europe. ORLADEYO received European Commission marketing authorization in April 2021 and is now available in over 30 countries.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); }...